Home › Trial NCT04466891
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
- Trial IDNCT04466891
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorJazz Pharmaceuticals
- Enrollment87
- Start date2020-10-01
- ConditionsHER2-amplified Biliary Tract Cancers
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.